Amwell (AMWL) Q4 2022: Converge Drives 28% of Visits, Signaling Platform Migration Inflection
Amwell’s accelerated migration to its Converge platform marked a pivotal transition quarter, with 28% of visits now on the new system. The company’s focus is shifting toward high-margin software and module upsell, as legacy platform risk recedes. Investor attention turns to the pace of bookings conversion and the sustainability of margin expansion as macro and health system headwinds persist.
Summary
- Platform Migration Inflection: Converge adoption is reshaping client relationships and revenue mix.
- Recurring Revenue Focus: Strategic emphasis is now on software and module expansion, not visit volume alone.
- 2023 Guide Sets Conservative Base: Management signals upside potential, but macro and sales cycle caution frame expectations.
Business Overview
Amwell is a digital health enablement company providing a cloud-based platform for hybrid care delivery. Its core business generates revenue through subscription software, professional services, and Amwell Medical Group (AMG), a virtual visit service. Major segments include software subscriptions for payers and providers, AMG visit revenue, and services such as care points and integration. The company’s Converge platform is designed to unify digital and physical care, supporting modular expansion and third-party integration.
Performance Analysis
Q4 marked a strategic transition as Amwell completed core development of Converge and ramped client migrations, with 28% of visits now on the platform, up from 16% in Q3. Total revenue grew year over year, supported by strong AMG visit demand driven by an intense flu season, while subscription revenue was flat sequentially as the company prioritized migration and implementation over new bookings. Active providers rose 11% year over year, reflecting sustained platform engagement and successful client retention during the transition.
Average contract values (ACV) increased for both health plans (+19%) and health systems (+13%), indicating that land-and-expand strategies are gaining traction, especially with large, multi-module deployments. Gross margin improved by 250 basis points to 42.4% in the quarter, aided by higher-margin service mix and urgent care volumes. Operating expenses reflected peak R&D investment, but management expects sequential declines as Converge development winds down.
- Module Expansion Traction: Clients are increasingly adopting multiple modules, driving higher ACV and deepening relationships.
- Visit Volume Volatility: AMG visit revenue benefited from seasonal flu, but management guides conservatively for 2023, anticipating normalization.
- Margin Structure Shifting: As platform migration completes, recurring software revenue is set to outpace visit-driven growth, supporting long-term profitability goals.
While the transition year muted near-term revenue acceleration, Amwell’s underlying metrics show a business pivoting from transactional visit revenue toward scalable, high-margin software and services.
Executive Commentary
"In Q4, we had another great quarter for client migrations, and Converge is scaling well. Specifically, visits on Converge continue to rise, and grew from 16% of total visits for the quarter in Q3 to 28% of total visits in Q4."
Ido Schoenberg, Chairman & CEO
"We are pleased to have been able to achieve our revenue guide and exceed our adjusted EBITDA guide for 2022... Over the long run, it's our goal to drive a steady revenue mix shift toward high margin recurring software revenue in pursuit of our long-term model."
Bob Shepardson, CFO
Strategic Positioning
1. Converge Platform as Core Growth Engine
Converge, Amwell’s unified digital care platform, is now the centerpiece of its client strategy, enabling both existing and new customers to consolidate fragmented workflows and integrate third-party modules. The platform’s open architecture supports rapid module adoption, driving higher contract values and stickier client relationships.
2. Upsell and Expansion Within Existing Clients
Management is prioritizing “same-store” growth by cross-selling new modules and services to current clients, particularly among large payers and health systems. The company’s land-and-expand approach is gaining traction, with clients like Elevance Health and Northern Light Health embracing multi-module deployments that extend beyond core telehealth.
3. Margin Expansion and Cost Discipline
Peak R&D investment in 2022 is now receding, with management guiding for sequential declines in development spend as Converge matures, freeing up resources for commercial execution. The shift toward higher-margin software and services is expected to steadily improve profitability, even as macro and client budgeting headwinds persist.
4. Strategic Client Validation and Referenceability
Amwell’s partnerships with industry leaders like CVS and Elevance Health serve as reference points for new business, validating the Converge platform’s scalability and value proposition. These relationships are expected to accelerate pipeline momentum and drive bookings in the second half of 2023 and into 2024.
5. Modular Ecosystem and Third-Party Integration
Converge’s open platform enables integration with hundreds of third-party programs, including behavioral health (SilverCloud), automated care (Conversa), and specialty modules from external partners. This ecosystem approach positions Amwell as an orchestrator, not just a provider, of digital health solutions.
Key Considerations
Amwell’s Q4 results highlight a business at an inflection point, shifting from legacy platform risk to a forward-looking, software-centric model. The following considerations frame the company’s strategic context for investors:
- Bookings-to-Revenue Lag: With an average five to six month implementation cycle, 2023 bookings momentum will primarily impact 2024 revenue acceleration.
- Client Retention and Upsell: Retaining strategic clients and expanding wallet share is central to the company’s growth thesis, especially as new logo additions remain lumpy.
- Macro and Budget Headwinds: Hospital and payer budget constraints could elongate sales and deployment cycles, tempering near-term growth despite robust demand signals.
- Module Demand Diversity: Behavioral health, navigation, and automated care are in high demand, but uptake varies by client segment and operational readiness.
- Margin Pathway Visibility: Cost discipline and the sunset of legacy R&D spend underpin the path to EBITDA break-even, with flexibility to adjust spend if macro risks materialize.
Risks
Key risks include elongated sales cycles and delayed client deployments due to macro uncertainty and constrained health system budgets. While management expresses confidence in demand and platform adoption, the pace of bookings conversion and upsell is subject to customer readiness and external economic factors. Churn at the low end, though limited, remains a risk if smaller clients opt for lower-cost alternatives or delay migrations.
Forward Outlook
For 2023, Amwell guided to:
- Revenue of $275 to $285 million, reflecting normalization of AMG visit volume and conservative module ramp assumptions
- Adjusted EBITDA loss of $150 to $160 million, with sequential improvement expected as R&D spend declines
Management emphasized:
- Bookings momentum will skew to the second half of the year, with revenue impact more visible in 2024
- Software subscription revenue is expected to grow faster than overall company revenue
Takeaways
- Migration Execution: The company has largely de-risked its platform transition, with Converge now driving a significant share of visits and client engagement.
- Recurring Revenue Shift: Strategic focus is on expanding high-margin, recurring software and module revenue, with client validation from industry leaders.
- 2023 as Setup Year: Investors should watch for bookings acceleration and module adoption as key signals for 2024 revenue and margin expansion.
Conclusion
Amwell’s Q4 results confirm the company’s successful platform migration and set the stage for a software-driven growth trajectory. The focus now shifts to accelerating bookings, deepening client relationships, and delivering on margin improvement as macro uncertainty persists.
Industry Read-Through
Amwell’s transition underscores an industry-wide pivot toward integrated, modular digital health platforms capable of supporting hybrid care models. The company’s open ecosystem approach and emphasis on enabling—not competing with—clients reflects a broader trend among digital health vendors to become orchestrators rather than siloed service providers. Health systems and payers are increasingly prioritizing platforms that unify fragmented digital tools and streamline patient and provider workflows, with behavioral health and automated care modules in high demand. The lag between bookings and revenue recognition signals that near-term growth across the sector may remain muted until large-scale deployments mature. Investors should monitor how quickly other digital health companies can execute platform migrations and shift their revenue mix toward recurring software and services.